We are live on ! Find out more
RAIN

Rain Oncology Inc. Common Stock

Delisted

RAIN was delisted on the 25th of January, 2024.

40 hedge funds and large institutions have $77.7M invested in Rain Oncology Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $75.1M → $77.7M (+$2.62M)

18% less funds holding

Funds holding: 4940 (-9)

37% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 19

67% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 15

Holders
40
Holders Change
-9
Holders Change %
-18.37%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
5
Reduced
15
Closed
19
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AB
51
Amalgamated Bank
New York
-$12K -2,368 Closed
SO
52
STRS Ohio
Ohio
-$8K -1,700 Closed
Legal & General Group
53
Legal & General Group
United Kingdom
-$8K -1,586 Closed
AIP
54
Ameritas Investment Partners
Nebraska
-$6K -1,230 Closed
Royal Bank of Canada
55
Royal Bank of Canada
Ontario, Canada
-$5K -978 Closed
UBS Group
56
UBS Group
Switzerland
-$4K -692 Closed
CS
57
Credit Suisse
Switzerland
+$27 +8 New
EI
58
Ellevest Inc
New York
+$154 +45 New
CAPTRUST Financial Advisors
59
CAPTRUST Financial Advisors
North Carolina
+$213 +62 New

RAIN Hedge Fund Activity: Q2 2022 in Review

40 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Rain Oncology Inc. Common Stock (RAIN) for Q2 2022, worth a combined $77.7M — up 3.5% from $75.1M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of RAIN and 12 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 5 added.

The largest buyer was UBS O'Connor, opening a new position worth an estimated $1.14M. The largest seller was BlackRock, cutting an estimated $2.27M.

  • 40 institutional investors held Rain Oncology Inc. Common Stock (RAIN) as of Q2 2022, down from 49 in Q1 2022.
  • Funds reported $77.7M of Rain Oncology Inc. Common Stock stock for Q2 2022, up 3.5% quarter-over-quarter.
  • 12 funds opened new Rain Oncology Inc. Common Stock positions in Q2 2022 and 19 closed out, a net change of -7 holders.
  • The largest Rain Oncology Inc. Common Stock buyer in Q2 2022 was UBS O'Connor, an estimated $1.14M added.
  • The largest Rain Oncology Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $2.27M sold.

Based on aggregated 13F filings for Q2 2022.